Novigenix Presents New Immuno-Transcriptomic Data for Prediction of Response to Immunotherapy in Metastatic Urothelial Cancer Patients

Newly discovered blood signature presented at ESMO 2020. 

LAUSANNE, SWITZERLAND  – Novigenix SA, a pioneer in Immuno-Transcriptomics for precision oncology, today announced a new Immuno-Transcriptomic signature for predicting response to immunotherapy in metastatic urothelial cancer patients. The data are presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress (17-21september 2020 at Virtual congress).


Immune checkpoint inhibitors (ICIs) have become one of the main treatments for patients with metastatic urothelial cancer (UC). With only a minority of patients (20%) showing benefit from ICIs, there is a significant unmet medical need for accurate liquid biopsy solutions for patient stratification.

In the study, whole blood Immuno-Transcriptome profiles were generated by RNA sequencing from 31 patients with metastatic UC patients that were treated with anti-PD-1. Samples were collected before and after 2-6 weeks of anti-PD-1 therapy. Clinical benefit was defined as Progression-Free Survival (PFS) ≥ 6 months.

In the training cohort, a final panel of 105 genes predicted clinical benefit from anti-PD-1 therapy with an area under the curve (AUC) of 0.95 (sensitivity 90%, specificity 69%).

“The performance data of the newly discovered immune-transcriptomic signature for predicting response to immunotherapy in metastatic urothelial cancer are very encouraging,” said Dr. Niven Mehra from Department of Medical Oncology at Radboud University, Netherland.  “A prospective study has been launched to validate the test in a new cohort”.

Whole blood ImmunoTranscriptomics is a powerful liquid biopsy tool for the early detection of cancer, and for therapy optimization. We look forward to providing new precision oncology solutions to support UC patients that benefit from ICIs, and to provide oncologists new insights into therapy response to anti-PD-1”, said Dr. Brian HashemiExecutive Chairman of Novigenix. 

About LITOseek

Novigenix’s Blood Immuno-Transcriptomic sequence platform, LITOseek, analyzes the gene expression modifications (mRNA signatures) induced by the host response to various triggers, such as the onset of cancer. Disease specific algorithms are developed through application of Artificial Intelligence on patient mRNA signatures in combination with clinical and medical parameters. The LITOseek platform has been designed and optimized for development of precision oncology solutions based on the human Immuno-Transcriptome, with continuous improvement of the predictive and adaptive algorithms.

About Department of Medical Oncology, Radboud University


For more information:



Dr. Brian Hashemi

Edwin Shankar






Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


Novigenix is committed to providing a new understanding of the human host response against cancer and its response to therapy. The Company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients, leading to significant improvement in medical outcomesNovigenix’s unique Immuno-Transcriptomics technology enables an accelerated identification of disease specific mRNA signatures of immune cells, which combined with machine learning and predictive algorithms, can provide new insights into onset and progression of disease. The Company has established a valuable multi-ethnical biobank of cancer patients and has launched its first Immuno-Transcriptomic molecular diagnostic blood test Colox® on the Swiss market for the early detection of colon cancer.